Digital health and healthcare DTC entities - including fertility clinics, OBGYNs, primary care providers and pharmacies - can utilize IHD's partner platform to offer consumers over 70 different at-home tests, from infectious disease and wellness to women's and men's health.
The platform bridges the gap between digital health services and diagnostics - creating a more complete customer experience with emphasis on fast turnaround times, actionable results, and superior customer service provided by IHD.
Accelerating at-home testing services for healthcare companies, IHD's new platform enables a better customer experience and outcomes, seamless technology integration, and custom kits built specifically for the unique mix of tests required by the partner and its patients.
IHD's health partners can leverage the company's end-to-end DaaS platform or select individual modules that fit into the brand's existing operation, such as logistics and clinical networks.
IHD serves as a collaborative and flexible partner while maintaining the highest standards of testing methodologies, quick turnaround times and affordability.
Innovative Health Diagnostics empowers every person by providing access to accurate, clinical testing, when and where it matters most. IHD services also include fertility and in vitro fertilization testing; FDA donor testing for families completing surrogacies; and COVID-19 polymerase chain reaction and antibody testing.
Caliway Biopharmaceuticals commences CBL-0204 Phase 2b study patient recruitment
Adiso Therapeutics completes Phase 1b multiple ascending dose clinical trial assessing ADS051
Pfizer receives FDA approval for RSV vaccine in older adults
Establishment Labs Receives CE Mark Approval for Minimally Invasive Surgical Tools
Lexicon Pharma's drug for heart failure gains US FDA approval
EU regulator looking to revoke Novartis' sickle cell drug marketing authorisation
Ipsen Pharma receives negative CHMP opinion for palovarotene as potential FOP treatment
CHMP recommends extending use of Veklury for COVID-19 in severe renal impairment
Endo Ventures announces bivalirudin injection US distribution agreement with MAIA Pharmaceuticals
AgonOx and Providence Cancer Institute announce PH-762 collaborative clinical trial initiation